TEM241108P63000
- 0.00
- 0.000.00%
Tempus AI Newsroom
Exciting Growth Potential Ahead for Tempus AI (TEM)
Morgan Stanley Maintains Tempus AI(TEM.US) With Buy Rating, Maintains Target Price $50
Loop Capital Maintains Tempus AI(TEM.US) With Buy Rating, Maintains Target Price $57
Morgan Stanley Maintains Tempus AI(TEM.US) With Buy Rating, Raises Target Price to $50
J.P. Morgan Maintains Tempus AI(TEM.US) With Buy Rating, Raises Target Price to $50
Tempus AI Reports Growth and Strategic Acquisition
Tempus AI Shares Fall After Reporting Q3 Loss, Deal to Acquire Ambry Genetics for $600 Million
10 Health Care Stocks Whale Activity In Today's Session
Tempus Stock Declines Despite Q3 Earnings & Revenues Beat Estimates
Tempus AI Shares Are Trading Lower After the Company Reported Mixed Q3 Financial Results. Also, the Company Announced It Entered Into an Agreement to Acquire Ambry Genetics.
Q3 2024 Tempus AI Inc Earnings Call
Needham Maintains Tempus AI(TEM.US) With Buy Rating, Raises Target Price to $56
Tempus AI, Inc. Class A (TEM) Gets a Hold From Piper Sandler
Analysts Are Bullish on These NA Stocks: Tempus AI, Inc. Class A (TEM), Astera Labs, Inc. (ALAB)
Express News | Tempus AI Inc : Needham Raises Target Price to $56 From $47
Tempus AI Inc (TEM) Q3 2024 Earnings Call Highlights: Robust Revenue Growth and Strategic ...
Express News | Konica Minolta Inc - 41 Bln Yen Gain From This Share Transfer Is Expected to Be Recorded in Second Half of Fiscal Year Ending March 31, 2025
Express News | Konica Minolta Inc - to Transfer Share of Ambry Genetics Corp to Tempus AI Inc to for $600 Mln
Express News | Konica Minolta Inc - Notice Regarding Change in a Consolidated Subsidiary (Transfer of Share) and Recording of Profit From Discontinued Operation Due to Share Transfer
Tempus Continues To Expect FY24 Revenue Of ~$700M, Which Represents ~32% YoY Growth And ~$(105M) In Adj EBITDA, An Improvement Of ~$50M Over 2023